Piper Sandler analyst Christopher Raymond raised the firm's price target on Regeneron to $500 from $435 and keeps an Overweight rating on the shares. Raymond raised his Eylea revenue estimates and price target based on two separate retinal specialist surveys, namely one fielded just before, and one after the ASRS Beovu safety communication. The analyst said that he cannot overstate the impact of these concerns, and sees a market that has been upended essentially overnight. Raymon added the he remains a buyer of Regeneron to levels approaching $500 a share.